<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, diagnosis, and treatment of miliary tuberculosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, diagnosis, and treatment of miliary tuberculosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, diagnosis, and treatment of miliary tuberculosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Bernardo, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Miliary tuberculosis (TB) refers to clinical disease resulting from hematogenous dissemination of <em>Mycobacterium tuberculosis</em>. The term "miliary" was coined in 1700 by John Jacobus Manget, who likened the appearance of the involved lung to millet seeds, with its surface covered with small, firm white nodules  (<a class="graphic graphic_picture graphicRef76174" href="/z/d/graphic/76174.html" rel="external">picture 1</a>). The term miliary TB was originally a pathologic and then a radiographic description; it is now used to denote all forms of progressive, widely disseminated hematogenous TB. The term also may be used more broadly (and incorrectly) by some to denote involvement at multiple sites, whether or not disease presents with the classic radiographic or pathologic nodular appearance characteristic of hematogenous spread. Miliary TB can arise as a result of progressive primary infection or via reactivation of a latent focus with subsequent spread via the bloodstream. </p><p>The clinical manifestations, diagnosis, treatment, and prevention of miliary TB will be reviewed here. The epidemiology and pathogenesis of miliary and extrapulmonary TB are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8029.html" rel="external">"Epidemiology and pathology of miliary and extrapulmonary tuberculosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Clinical manifestations of miliary TB are most likely to be subacute or chronic; less commonly, acute presentations also occur. Patients with subacute or chronic disease may present with failure to thrive [<a href="#rid1">1</a>], fever of unknown origin [<a href="#rid2">2,3</a>], and/or dysfunction of one or more organ systems [<a href="#rid4">4</a>]. Night sweats are frequent; rigors are unusual [<a href="#rid5">5,6</a>]. In one series including 38 patients, the median duration of illness prior to clinical presentation was two months [<a href="#rid2">2</a>]. The most common extrapulmonary sites include the lymphatic system, bones and joints, liver, central nervous system (CNS), and adrenal glands.</p><p>Acute miliary TB may be fulminant, including multiorgan system failure [<a href="#rid7">7</a>], a syndrome of septic shock [<a href="#rid8">8</a>], and acute respiratory distress syndrome (ARDS) [<a href="#rid9">9,10</a>]. Miliary TB is a relatively rare cause of acute respiratory failure and ARDS [<a href="#rid11">11-13</a>]; one study in South Africa (where the prevalence of TB is very high) noted approximately 2 percent of cases of ARDS were associated with disseminated TB [<a href="#rid14">14</a>]. The diagnosis of TB is more likely to be delayed or missed in patients presenting with acute respiratory failure rather than more typical symptoms of pulmonary or pleural TB [<a href="#rid15">15</a>]. Patients who develop miliary TB during primary infection can present with relatively acute onset and rapid clinical course. (See  <a class="medical medical_review" href="/z/d/html/7026.html" rel="external">"Pulmonary tuberculosis: Clinical manifestations and complications"</a>.)</p><p>Symptoms and signs of miliary TB are described in the tables  (<a class="graphic graphic_table graphicRef60000" href="/z/d/graphic/60000.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef63136" href="/z/d/graphic/63136.html" rel="external">table 2</a>). Much of the data on clinical features of miliary TB comes from large retrospective series  (<a class="graphic graphic_table graphicRef77719" href="/z/d/graphic/77719.html" rel="external">table 3</a>) [<a href="#rid1">1,2,16-19</a>]. These studies include a relatively large number of patients though differ markedly by year, inclusion criteria, country, and type of medical center; therefore, direct comparisons are difficult.</p><p>Pulmonary disease has been observed in more than 50 percent of patients with miliary TB in most series [<a href="#rid16">16,17</a>]. Patients with miliary TB that involves the lungs may have dyspnea or cough and rales or rhonchi on physical examination; hypoxemia is common. Pleuritic chest pain with accompanying pleural rub or other signs of a pleural effusion have also been well described.</p><p>Autopsy series of miliary TB describe seeding of every organ in the body [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Signs and symptoms of liver involvement in disseminated TB include diffuse abdominal pain or pain localizing to the right upper quadrant, nausea, vomiting, and diarrhea [<a href="#rid21">21,22</a>]. Cholestatic jaundice in miliary TB is also well described. Rarely, fulminant hepatic failure can occur [<a href="#rid23">23</a>]. Liver function test abnormalities are common; one series noted elevated alkaline phosphatase and transaminases in 83 and 42 percent of patients, respectively [<a href="#rid16">16</a>]. Histopathologic sections of involved liver demonstrate scattered granulomatous lesions that, on gross examination, have the appearance of millet seeds  (<a class="graphic graphic_picture graphicRef83409" href="/z/d/graphic/83409.html" rel="external">picture 2</a>) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system lesions may occur diffusely throughout the brain and usually are not centered around the ventricles or basal cisterns (as seen in TB meningitis). In one series, meningeal involvement was evident postmortem in 54 percent of cases of miliary TB [<a href="#rid20">20</a>]. In another study including seven patients with radiographic pulmonary miliary TB and no clinical CNS findings, all had brain lesions on magnetic resonance imaging (MRI) [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">"Central nervous system tuberculosis: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal involvement in disseminated TB has been described in as many as 40 percent of autopsies [<a href="#rid18">18,26</a>]. Overt adrenal insufficiency is less common, occurring in 1 percent of reported cases of miliary TB [<a href="#rid16">16,26</a>]. In a prospective study including 30 patients with miliary TB, adrenal function was abnormal in one case [<a href="#rid27">27</a>]. Another series including 55 patients with TB involvement of the adrenal gland noted 12 percent presented with clinical manifestations of Addison's disease [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults"</a>.)</p><p></p><p>Mycobacteria can reach the liver by hematogenous dissemination (miliary) or by local spread from the gastrointestinal tract or the abdomen. A systematic review including 618 cases of hepatic TB noted miliary disease accounted for 79 percent of hepatic TB, usually accompanied by lung involvement; focal disease, including abscess formation or biliary tract TB, accounted for the remaining 21 percent [<a href="#rid28">28</a>]. Presenting findings described in 11 case series included hepatomegaly, fever, respiratory symptoms, abdominal pain, and weight loss. Imaging by computed tomography (CT) or ultrasound confirms liver involvement but is not specific for the diagnosis.</p><p>Tuberculous peritonitis usually develops following spread of infection from adjacent organs or by hematogenous spread in miliary disease. It should be suspected in patients at risk for TB who present with ascites. Symptoms of fever, fatigue, and abdominal pain are common. Ascites fluid usually demonstrates lymphocytosis, elevated protein, and elevated inflammatory markers. Culture of ascites fluid or of peritoneal tissue is required to confirm the diagnosis. The surface of the peritoneum may demonstrate focal granulomatous lesions on visual examination that may appear like miliary disease; biopsy of these lesions demonstrates caseating granulomas with or without acid-fast staining organisms. (See  <a class="medical medical_review" href="/z/d/html/1238.html" rel="external">"Abdominal tuberculosis"</a>.)</p><p>Central nervous system disease, such as meningitis or tuberculoma, was observed in 15 to 20 percent of patients with TB in two large series [<a href="#rid16">16,17</a>]. Among patients with tuberculous meningitis, about one-third to one-half in one series had miliary TB [<a href="#rid20">20</a>]. In a study of seven patients with miliary pulmonary TB and no neurologic findings, all patients had evidence of CNS disease by MRI [<a href="#rid25">25</a>].</p><p>Other manifestations of miliary TB include laryngitis [<a href="#rid29">29</a>], otitis media [<a href="#rid30">30</a>], and thyroid involvement with clinical hyperthyroidism or hypothyroidism [<a href="#rid31">31</a>].</p><p>The diagnosis of miliary TB is often missed due to the nonspecific nature of the presentation. In one United States review, approximately 20 percent of miliary TB cases were diagnosed postmortem [<a href="#rid32">32</a>]. Among patients with human immunodeficiency virus (HIV) in Africa, previously unrecognized disseminated TB has been identified at autopsy in as many as 40 percent of hospital deaths [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H10"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>Many laboratory abnormalities may be observed in miliary TB  (<a class="graphic graphic_table graphicRef76492" href="/z/d/graphic/76492.html" rel="external">table 4</a>). Hematologic abnormalities are prominent. Normocytic, normochromic anemia is seen in approximately one-half of the patients in most series. Most patients have a normal white blood cell count, but leukopenia and leukocytosis occur in a minority of patients with roughly equal frequency. Leukemoid reactions are also described and may be mistaken for leukemia [<a href="#rid33">33,34</a>]. Monocytosis occurs but is less common. Thrombocytopenia and thrombocytosis are also reported.</p><p>Pancytopenia, which should raise concern for miliary TB, may be due to marrow infiltration alone or may be a manifestation of an underlying hematologic disorder [<a href="#rid35">35</a>]. Cases of the histiocytic hemophagocytic syndrome associated with miliary TB have also been described [<a href="#rid36">36</a>].</p><p>Overt disseminated intravascular coagulation is rare; it has been described in acute, fulminant disease. Milder coagulation abnormalities have been described more frequently [<a href="#rid16">16</a>]. The erythrocyte sedimentation rate and other acute-phase reactants are elevated in the majority of patients with miliary TB. Polyclonal gammaglobulinemia is also common [<a href="#rid2">2</a>].</p><p>Hyponatremia may be observed; it is presumed to be due to the same problems with regulation of antidiuretic hormone seen in other pulmonary processes [<a href="#rid2">2</a>]. Hypercalcemia is rare but may be seen [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a>.)</p><p>Sterile pyuria was found in 32 percent of patients with miliary TB in one series [<a href="#rid2">2</a>]. Urine cultures may also be positive for <em>M. tuberculosis</em> in miliary TB in the absence of an abnormal urine sediment.</p><p class="headingAnchor" id="H11"><span class="h1">RADIOGRAPHIC IMAGING</span><span class="headingEndMark"> — </span>Two series of cases of miliary TB provide an excellent overview of pulmonary findings [<a href="#rid2">2,16</a>]. More than two-thirds of patients with the diagnosis of disseminated TB had a chest radiograph with a miliary pattern.</p><p class="headingAnchor" id="H12"><span class="h2">Chest radiography</span><span class="headingEndMark"> — </span>The classic appearance in miliary disease is a faint, reticulonodular infiltrate distributed fairly uniformly throughout the lungs  (<a class="graphic graphic_diagnosticimage graphicRef63302" href="/z/d/graphic/63302.html" rel="external">image 1</a>). This miliary pattern may become apparent days or weeks after presentation [<a href="#rid16">16,17,19</a>]. This finding is thought to reflect nodular interstitial spread without significant alveolar involvement, although it has been demonstrated that, by the time the miliary nodules are large enough to be appreciated on a plain chest radiograph, they typically involve the adjacent alveoli [<a href="#rid38">38</a>].</p><p>Conversely, pathologic conditions that initially involve alveoli, such as alveolar hemorrhage, pulmonary edema, or inhalational diseases, can appear initially as small nodules. These so-called "acinar nodules" are described as larger (5 to 10 mm) and more heterogeneous than classic miliary TB, but overlap occurs, making the appearance of many of these conditions indistinguishable [<a href="#rid39">39</a>]. The differential diagnosis of a miliary chest radiography pattern is summarized in the table  (<a class="graphic graphic_table graphicRef70568" href="/z/d/graphic/70568.html" rel="external">table 5</a>).</p><p>Other chest radiograph abnormalities include pleural reactions, hilar or mediastinal adenopathy, and other evidence of active or healed parenchymal TB (interstitial or alveolar infiltrates or cavities). A miliary pattern can be seen in addition to non-miliary disease. Normal chest radiographs may be observed in up to one-half of patients with disseminated TB [<a href="#rid40">40</a>]. In some cases, abnormalities may be subtle and appreciated only after review with an experienced chest radiologist.</p><p class="headingAnchor" id="H13"><span class="h2">Computed tomography</span><span class="headingEndMark"> — </span>High-resolution computed tomography (HRCT) of the chest is more sensitive for miliary TB than plain chest radiography [<a href="#rid41">41</a>]. Numerous 2 to 3 mm nodules can be visualized distributed throughout the lung  (<a class="graphic graphic_diagnosticimage graphicRef77071" href="/z/d/graphic/77071.html" rel="external">image 2</a>). Septal thickening usually accompanies these nodules. These findings are sensitive but not necessarily specific for miliary TB. In series correlating clinical and pathologic findings with HRCT, disseminated nodules were found in many other infections (<em>Haemophilus influenzae</em>, <em>Mycoplasma pneumoniae</em>, <em>Candida albicans</em>) and noninfectious diseases (sarcoidosis, metastatic adenocarcinoma, lymphoma, amyloidosis, hypersensitivity pneumonitis, and pneumoconiosis) [<a href="#rid42">42,43</a>].</p><p>Other nonspecific findings on chest CT can be observed in miliary TB. As an example, in one study, ground-glass opacities covering &gt;50 percent of the lung field were seen in 20 percent of patients with miliary TB [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H90644925"><span class="h2">Positron emission tomography CT</span><span class="headingEndMark"> — </span><sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET) computed tomography (CT) is becoming more widely used for the evaluation of malignancies [<a href="#rid45">45</a>]. Uptake of FDG is proportional to glycolysis within inflammatory cells such as neutrophils, activated macrophages, and lymphocytes as well as tumor cells, and regions of high uptake can be seen at sites of inflammation or infection such as in pulmonary and extrapulmonary sites of disease [<a href="#rid46">46</a>]. Findings are nonspecific for infection or neoplasm, and FDG-PET CT has not been systematically studied in miliary TB. Perhaps the most useful application of this technology will be to define sites of disease and monitor response to treatment [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Other imaging</span><span class="headingEndMark"> — </span>Gallium scans can show diffuse pulmonary and extrapulmonary uptake in miliary TB [<a href="#rid48">48</a>]. However, sensitivity and specificity are limited; patients with miliary TB and evidence of miliary patterns on chest imaging may have negative gallium scans.</p><p class="headingAnchor" id="H15"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of miliary TB should be suspected in patients with relevant clinical manifestations such as fever, night sweats, and organ dysfunction in the context of relevant epidemiologic or exposure history. The diagnosis is established by identifying the organism obtained from a biopsy sample in culture.</p><p>The diagnosis can be challenging due to nonspecific clinical symptoms and signs and poor diagnostic tools [<a href="#rid49">49</a>]. Careful evaluation of extrapulmonary findings is warranted, whether systemic disease is suspected in the setting of known pulmonary TB or whether extrapulmonary disease is the initial presenting feature. The nature and scope of extrapulmonary findings identified on diagnostic evaluation may influence the approach to treatment.</p><p class="headingAnchor" id="H13124464"><span class="h2">Clinical approach</span><span class="headingEndMark"> — </span>Clinical evaluation begins with a thorough history and physical examination, including a dilated funduscopic examination since choroidal tubercles are characteristic of miliary TB and, if present, strongly support the diagnosis of miliary TB [<a href="#rid24">24</a>]. One large autopsy series that included eye examinations found tubercles in 50 percent of eyes [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/7999.html" rel="external">"Tuberculosis and the eye"</a>.)</p><p>In general, an evaluation for pulmonary disease is warranted in all patients in whom disseminated TB is suspected  (<a class="graphic graphic_table graphicRef80879" href="/z/d/graphic/80879.html" rel="external">table 6</a>), including chest radiography (followed by computed tomography [CT] if warranted), sputum for acid-fast smear and culture, nucleic acid amplification (NAA) testing, and <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) or interferon-gamma release assay (IGRA; see below). If sputum cannot be obtained (via expectoration or induction) or if sputum is acid-fast bacilli smear negative, evaluation via bronchoscopic sampling (including bronchial brushings and/or transbronchial biopsy) is warranted [<a href="#rid50">50</a>]. In addition, mycobacterial blood culture should be performed using a lysis centrifugation or automated broth system designed for mycobacterial culture [<a href="#rid51">51-53</a>]. (See <a class="local">'Acid-fast smear and culture'</a> below and <a class="local">'Molecular tests'</a> below and  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p>The subsequent diagnostic approach should be tailored to localizing signs or symptoms of disease involvement:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with neurologic signs or symptoms should undergo neuroimaging and lumbar puncture (if feasible and if there is no indication of increased intracranial pressure). The most common radiographic findings in tuberculous meningitis are basal meningeal enhancement and/or hydrocephalus. Cerebrospinal fluid (CSF) should be analyzed for cell count, protein, and glucose concentrations as well as acid-fast staining and culture for bacterial and mycobacterial organisms. (See  <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">"Central nervous system tuberculosis: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the setting of pleural effusion, pericardial effusion, or ascites, fluid should be obtained for evaluation of cell count, protein, glucose, and lactate dehydrogenase (LDH) concentrations as well as acid-fast staining and culture for bacterial and mycobacterial organisms [<a href="#rid50">50</a>]. Pleural biopsy is warranted in the setting of moderate to high suspicion for TB when pleural fluid evaluation is not diagnostic. (See  <a class="medical medical_review" href="/z/d/html/8012.html" rel="external">"Tuberculous pleural effusion"</a> and  <a class="medical medical_review" href="/z/d/html/8002.html" rel="external">"Tuberculous pericarditis"</a> and  <a class="medical medical_review" href="/z/d/html/1238.html" rel="external">"Abdominal tuberculosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with symptoms localizing to other extrapulmonary sites (lymph nodes, bones/joints, skin, and other sites) should undergo evaluation as warranted depending on the involved organ system. Radiographic imaging may be warranted. Tissue biopsy may be required to establish a definitive diagnosis. (See  <a class="medical medical_review" href="/z/d/html/8001.html" rel="external">"Tuberculous lymphadenitis"</a> and  <a class="medical medical_review" href="/z/d/html/7658.html" rel="external">"Bone and joint tuberculosis"</a> and  <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">"Cutaneous manifestations of tuberculosis"</a>.)</p><p></p><p>Biopsy specimens from the lung, bone marrow, pericardium, lymph nodes, bones, joints, bowel, liver, brain, or other tissues allow for both histopathologic examination and culture. Liver biopsies are generally associated with the highest yield for diagnosis of extrapulmonary TB. In two series, granulomas were demonstrated more frequently in liver biopsies (91 to 100 percent) than bone marrow biopsies (31 to 82 percent) or transbronchial biopsies (72 and 63 percent) [<a href="#rid2">2,16</a>]. Lymph nodes and serosal biopsies also had high yields in patients in these series. The biopsy yield is likely to be increased in the setting of associated clinical or laboratory abnormalities. Biopsy specimens should be collected with and without fixative; culture requires specimens without fixative. (See <a class="local">'Histopathology'</a> below.)</p><p>The <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) and interferon-gamma release assay (IGRA) are tools designed for diagnosis of TB infection; a positive result supports (but cannot be used to establish) a diagnosis of active TB disease, and a negative result does not rule out active TB disease. Anergy is observed more frequently among patients with miliary TB than those with pulmonary or isolated extrapulmonary involvement and may be as high as 68 percent [<a href="#rid54">54</a>]. Reports of IGRA sensitivity among patients with miliary TB have been inconsistent. One study including 44 patients with miliary TB noted positive results with the QuantiFERON-TB Gold in-tube assay in 68 percent of cases [<a href="#rid55">55</a>]. Another study including 43 patients with miliary TB tested with the ELISPOT assay noted sensitivity of 93 percent [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p>There is no role for serologic testing in the diagnosis of TB; such tests have very low specificity [<a href="#rid57">57-60</a>]. While large numbers of individuals worldwide have TB antibodies, only about 10 percent of them go on to develop active disease.</p><p class="headingAnchor" id="H13124472"><span class="h2">Diagnostic tools</span></p><p class="headingAnchor" id="H17"><span class="h3">Acid-fast smear and culture</span><span class="headingEndMark"> — </span>Acid-fast smear and culture of tissue, fluid, or drainage from an infected locus is the standard tool for establishing the diagnosis of TB [<a href="#rid50">50</a>]. Acid-fast microscopy may support a diagnosis of TB, especially if organisms or caseating granulomas are seen. The frequency of positive smears or cultures is summarized in the table  (<a class="graphic graphic_table graphicRef70362" href="/z/d/graphic/70362.html" rel="external">table 7</a>) [<a href="#rid2">2,16</a>]. These data make several important points:</p><p class="bulletIndent1"><span class="glyph">●</span>Smears for acid-fast bacilli were positive in a minority of patients when only a single site was sampled; the probability of a positive smear increased with the number of sites sampled. Thus, when possible, samples of multiple sites (sputum, gastric aspirate, pleural fluid, ascites, urine) should be examined for the presence of acid-fast bacilli.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastric aspirate cultures were frequently positive in these series. However, it was not clear how often they were positive when sputum smears were negative. It may be reasonable to obtain gastric aspirates if sputum smears are not available or negative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bronchoscopy may be warranted if acid-fast bacilli are not detected at multiple sites (sputum, gastric aspirate, pleural fluid, ascites, urine); bronchoscopy is most useful when there is evidence of pulmonary involvement on chest radiography [<a href="#rid61">61,62</a>]. In the setting of acute presentation or in the absence of rapid diagnostic tools, prompt bronchoscopy is warranted. (See <a class="local">'Molecular tests'</a> below.)</p><p></p><p>Smears should be stained with the acid-fast fluorochrome dye, auramine-O, which is more sensitive than the conventional Ziehl-Nielsen stain [<a href="#rid63">63</a>]. Where available and validated appropriately, rapid probes (not approved by the US Food and Drug Administration [FDA]) may be applied to smear-positive sputum specimens to confirm the diagnosis of <em>M. tuberculosis</em> [<a href="#rid64">64</a>]. Specimens also should be inoculated into a commercial liquid-medium automated detection system (eg, BACTEC MGIT 960), which is faster and more sensitive than standard techniques using solid medium for the isolation of <em>M. tuberculosis</em> [<a href="#rid65">65</a>]. <em>M. tuberculosis</em> can be differentiated from isolated nontuberculous mycobacteria by hybridization using FDA-approved nucleic acid probes where available or biochemical methods or by other non-FDA-approved methods that have been validated appropriately by the laboratory, such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) [<a href="#rid66">66</a>].</p><p>Mycobacterial blood cultures (preferably using lysis centrifugation techniques) should be performed in all patients in whom hematogenous dissemination is suspected [<a href="#rid51">51</a>]. Positive blood cultures in disseminated TB are relatively rare, though they may be observed in immunocompromised patients, including those with HIV infection [<a href="#rid53">53,67</a>]. Species identification is important since positive mycobacterial blood cultures may also occur in the setting disseminated <em>Mycobacterium bovis</em> Bacillus Calmette-Guérin (BCG) infection (eg, from patients receiving intravesical installation of BCG to treat bladder cancer) and disseminated <em>Mycobacterium avium</em> (eg, in untreated patients with advanced HIV infection).</p><p class="headingAnchor" id="H13124590"><span class="h3">Histopathology</span><span class="headingEndMark"> — </span>Histopathology of tissue biopsy specimens in the setting of TB typically demonstrates granulomatous inflammation [<a href="#rid50">50</a>]. Granulomas of TB characteristically contain epithelioid macrophages, Langhans giant cells, and lymphocytes  (<a class="graphic graphic_picture graphicRef67234" href="/z/d/graphic/67234.html" rel="external">picture 3</a>). The centers of tuberculous granulomas often have characteristic caseation ("cheese-like") necrosis; organisms may or may not be seen with acid-fast staining. The demonstration of characteristic caseating granulomas on a tissue section in the appropriate clinical and epidemiologic circumstances strongly supports a diagnosis of active TB, but it is not pathognomonic; culture is required to establish a laboratory diagnosis.</p><p class="headingAnchor" id="H18"><span class="h3">Molecular tests</span><span class="headingEndMark"> — </span>In regions where available, molecular tests can be useful rapid diagnostic tools.</p><p class="headingAnchor" id="H19"><span class="h4">Nucleic acid amplification</span><span class="headingEndMark"> — </span>NAA assays are used to amplify the quantity of <em>M. tuberculosis</em> ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) in diagnostic specimens where organisms may be present in amounts too small to be seen by routine staining techniques. These techniques are sensitive for rapid detection of <em>M. tuberculosis</em> in a variety of specimens, including blood, sputum, and urine [<a href="#rid50">50,68-74</a>]. NAA tests available in the United States have been approved by the FDA only for use with sputum or respiratory secretions; use on other specimen types is off-label use. Sensitivity of these tests is better in smear-positive samples, and a positive test in the appropriate clinical setting likely represents pulmonary TB [<a href="#rid50">50,75,76</a>]. However, a negative NAA test result may not be used to exclude TB because false-negative results are common [<a href="#rid50">50</a>].</p><p>The primary advantage of NAA tests is that a positive result to establish a diagnosis may be available within 24 hours. The United States Centers for Disease Control and Prevention (CDC) has published recommendations for the use of these tests in the diagnosis of TB [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p class="headingAnchor" id="H33120436"><span class="h5">Xpert MTB/RIF assay</span><span class="headingEndMark"> — </span>The Xpert MTB/RIF assay is an automated nucleic acid amplification test that can simultaneously identify <em>M. tuberculosis</em> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> resistance. The Xpert MTB/RIF assay is approved by the FDA only for testing sputum in adults, although it may be applied in a non-approved indication to non-sputum samples following a validation process for that indication by the laboratory performing the test [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p class="headingAnchor" id="H906587244"><span class="h5">Other assays</span><span class="headingEndMark"> — </span>Many hospital and clinical laboratories offer nucleic acid amplification testing for <em>M. tuberculosis</em> complex using molecular methods (eg, polymerase chain reaction) not approved by the FDA but validated internally within the testing laboratory according to a written protocol. These "in-house" tests generally offer high specificity and, if positive, may be useful in supporting a clinical diagnosis of TB. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults", section on 'Molecular testing'</a>.)</p><p class="headingAnchor" id="H2622104686"><span class="h3">Urine antigen test in HIV infection</span><span class="headingEndMark"> — </span>Urine-based detection of mycobacterial cell wall glycolipid lipoarabinomannan (urine LAM assay) is an assay for diagnosis of TB [<a href="#rid79">79-86</a>]. The urine LAM test is an important adjunctive diagnostic tool for settings with high incidence of HIV and TB. Issues related to use of this assay are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults", section on 'Urine antigen test in HIV infection'</a>.)</p><p class="headingAnchor" id="H16773712"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of miliary TB is broad and depends on the degree of dissemination and the involvement of specific tissues and organs. The anatomic distribution of granulomatous lesions within the lung on high-resolution computed tomography (CT) scanning can be helpful for distinguishing hematogenously disseminated processes like miliary TB (which exhibits a random distribution of lesions) from airway-centered disorders (such as inhalational diseases) and lymphatic-centered processes (such as sarcoidosis) [<a href="#rid87">87</a>].</p><p>A miliary pattern on chest imaging may be due to many conditions, including  (<a class="graphic graphic_table graphicRef70568" href="/z/d/graphic/70568.html" rel="external">table 5</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Histoplasmosis – Clinical manifestations of histoplasmosis include fever, fatigue, hepatosplenomegaly, and pancytopenia. Pulmonary manifestations may include pneumonia, adenopathy, lung mass, lung nodule(s), and/or cavitary lung disease. The diagnosis is established via histopathology, culture, antigen detection, or serology. (See  <a class="medical medical_review" href="/z/d/html/2451.html" rel="external">"Diagnosis and treatment of pulmonary histoplasmosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoidosis – Clinical manifestations of sarcoidosis include cough, dyspnea, chest pain, eye lesions, and/or skin lesions. Bilateral hilar adenopathy is a classic chest radiograph finding; it may be absent and/or occur in combination with parenchymal opacities. The diagnosis is based on compatible clinical and radiographic manifestations and histopathologic detection of noncaseating granulomas. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypersensitivity pneumonia – Subacute or chronic hypersensitivity pneumonitis is an inhalational lung disease characterized by productive cough, dyspnea, fatigue, anorexia, and weight loss. The diagnosis is based upon exposure history, clinical assessment, radiographic and physiologic findings, and the response to avoidance of the suspected etiologic agent. (See  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Talc granulomatosis – Clinical manifestations of talc granulomatosis are usually nonspecific such as dyspnea, cough, or an increase in sputum production. Some patients are asymptomatic; night sweats, weight loss, and hemoptysis occur less commonly. Clinical history and radiographic findings are often highly suggestive; when the diagnosis is unclear, flexible bronchoscopy with bronchoalveolar lavage is warranted. (See  <a class="medical medical_review" href="/z/d/html/4370.html" rel="external">"Foreign body granulomatosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary hemosiderosis – The clinical presentation of pulmonary hemosiderosis varies from an acute-onset illness with hemoptysis and dyspnea to an insidious process characterized by fatigue, anemia, and slowly progressive exertional dyspnea. Radiography demonstrates bilateral ground-glass alveolar opacities. Hemosiderin-laden alveolar macrophages may be identified in sputum, bronchoalveolar lavage fluid, and lung biopsy. (See  <a class="medical medical_review" href="/z/d/html/4318.html" rel="external">"Idiopathic pulmonary hemosiderosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary bronchoalveolar carcinoma – Radiographic findings of bronchioloalveolar carcinoma may be variable and range from a solitary or limited number of nodules to more extensive miliary disease or diffuse parenchymal infiltrates. The diagnosis is established via histopathology. (See  <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Adenocarcinoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor metastases – Metastatic disease from primary neoplasms such as thyroid or kidney may present with radiographic nodules or a miliary appearance. The diagnosis is established via histopathology. (See  <a class="medical medical_review" href="/z/d/html/6986.html" rel="external">"Diagnostic evaluation of the incidental pulmonary nodule"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spread of pyogenic infection from a remote site – Bacterial infection may reach the lung via hematogenous spread and/or via septic embolization. The diagnosis is established via bacterial culture. (See  <a class="medical medical_review" href="/z/d/html/2142.html" rel="external">"Complications and outcome of infective endocarditis", section on 'Septic embolization'</a>.)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>In general, the approach to antimicrobial therapy for treatment of miliary TB consists of the traditional regimen (≥6 months) for treatment of pulmonary TB [<a href="#rid88">88</a>]. While the data suggest that this approach is successful, individualization of regimens may be warranted. The rifapentine-moxifloxacin-based four-month regimen should not be used for treatment of extrapulmonary disease [<a href="#rid89">89,90</a>]. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a>.)</p><p>Modifications to the standard drug regimen may be justified in the setting of drug-resistant TB. In addition, longer duration of therapy may be warranted for children, immunocompromised hosts, patients with a large organism burden, and patients with a slow microbiologic or clinical response. Longer duration of therapy is also warranted for patients with disease involving the central nervous system (CNS), some patients with bone or joint disease, and some cases of lymphadenitis (a site of early relapse in anecdotal reports) [<a href="#rid91">91</a>]. Depending on the site(s) and scope of disease, surgical intervention may be needed for diagnostic and/or therapeutic management.</p><p>Data on the role of corticosteroids in patients with miliary TB are limited; results of case reports and small clinical series using corticosteroids in miliary TB are conflicting [<a href="#rid24">24</a>]. In some circumstances, corticosteroids are warranted for treatment of TB involving the CNS [<a href="#rid92">92</a>] or pericardium [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/z/d/html/128001.html" rel="external">"Central nervous system tuberculosis: Treatment and prognosis", section on 'Glucocorticoids'</a>.) </p><p class="headingAnchor" id="H23"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>The clinical course and outcomes of miliary TB have improved markedly between the preantibiotic and postantibiotic eras [<a href="#rid20">20,94</a>]. In the United States Veteran's Administration study of miliary TB (excluding meningitis), the attributable mortality dropped successively (from nearly 100 percent) with the introduction of each new drug. Mortality dropped with the introduction of <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> (to 47 percent), with streptomycin plus <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">para-aminosalicylic acid</a> (to 18 percent), and with isoniazid-based combination therapy (to 5 percent) [<a href="#rid94">94</a>]. Subsequently, two large series noted mortality of approximately 20 percent [<a href="#rid2">2,16</a>]. These studies included patients with a broad range of underlying diseases and did not exclude meningeal TB. Since the introduction of isoniazid-based therapy, case series have documented shorter duration of fever and more rapid clinical and radiographic improvement. In one study, the median time to defervescence was 7 days (range 1 to 55 days); 76 percent of patients were afebrile within 14 days of the initiation of therapy [<a href="#rid16">16</a>]. Disseminated TB continues to be associated with a high mortality rate in patients with acquired immunodeficiency syndrome (AIDS) who are not on antiretroviral therapy [<a href="#rid95">95</a>].</p><p>The factors that contribute to survival in miliary TB are difficult to assess, since the literature is generally limited to retrospective case studies and includes patients with variable clinical and laboratory presentations. However, central nervous system disease appears to be an independent predictor of mortality in most studies [<a href="#rid2">2,17,94</a>]. Pancytopenia or lymphopenia were poor prognostic indicators in some studies [<a href="#rid16">16,35</a>]. Age, late presentation, serious underlying disease, and a nonreactive <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> are cited in other studies as predictors of mortality [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H24"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Miliary TB can be prevented by treatment of latent TB infection. In addition, childhood administration of Bacillus Calmette-Guérin in endemic areas reduces the incidence of miliary TB. A large meta-analysis found a 78 percent protective effect of the vaccine against miliary TB [<a href="#rid97">97</a>]. (See  <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/8022.html" rel="external">"Prevention of tuberculosis: BCG immunization and nutritional supplementation"</a>.)</p><p class="headingAnchor" id="H185260432"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111822.html" rel="external">"Society guideline links: Diagnosis and treatment of tuberculosis"</a>.)</p><p class="headingAnchor" id="H6857598"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Miliary tuberculosis (TB) refers to clinical disease resulting from the hematogenous dissemination of <em>Mycobacterium tuberculosis </em>and is characterized by the presence of small, firm white nodules resembling millet seeds. Miliary TB can arise as a result of progressive primary infection or via reactivation of a latent focus with subsequent spread. The clinical presentation of miliary TB is highly variable; manifestations can be acute but are more likely to be subacute or chronic. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– (see <a class="local">'Clinical manifestations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Signs and symptoms</strong> – Acute disease may be fulminant, including multiorgan system failure, a syndrome of septic shock, and acute respiratory distress syndrome (ARDS). Patients with subacute or chronic disease may present with failure to thrive, fever of unknown origin, or dysfunction of one or more organ systems. Symptoms generally are related to the site(s) of disease involvement. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sites of involvement</strong> – The most common sites of involvement include the lungs, the lymphatic system, bones and joints, liver, central nervous system (CNS), and adrenal glands. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong> – The most common laboratory abnormalities include anemia and other hematologic findings. Other laboratory abnormalities may include elevated acute-phase reactants, hyponatremia, hypercalcemia, and sterile pyuria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiographic imaging</strong> – In miliary disease, the classic chest radiograph appearance is a faint, reticulonodular infiltrate distributed fairly uniformly throughout the lungs  (<a class="graphic graphic_diagnosticimage graphicRef63302" href="/z/d/graphic/63302.html" rel="external">image 1</a>). Other chest radiograph abnormalities include pleural reactions, hilar or mediastinal adenopathy, interstitial or alveolar infiltrates, or cavities. Computed tomography of the chest is more sensitive for evaluation of miliary TB than plain chest radiography. (See <a class="local">'Laboratory findings'</a> above and <a class="local">'Radiographic imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical approach </strong>– (see <a class="local">'Clinical approach'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Clinical evaluation for miliary TB begins with a thorough history and physical examination, including a dilated funduscopic examination. In general, evaluation for pulmonary disease and mycobacterial blood cultures are warranted in all patients in whom disseminated TB is being considered. In regions where available, molecular tests can be useful rapid diagnostic tools.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The subsequent diagnostic evaluation should be tailored to localizing signs or symptoms of disease involvement. Patients with neurologic signs or symptoms should undergo neuroimaging and lumbar puncture (if feasible and not contraindicated). In the setting of pleural effusion, pericardial effusion, or ascites, fluid should be obtained for evaluation and a biopsy strongly considered. Radiographic imaging of the involved site(s) may be warranted for patients with symptoms referable to the CNS, gastrointestinal tract, genitourinary tract, bones/joints, or lymph nodes. Suspected genitourinary disease should prompt urine acid-fast bacillus culture. Depending on the involved site(s), tissue biopsy may be required to establish a definitive diagnosis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Histopathology</strong> - Biopsy specimens allow for both histopathologic examination and acid-fast culture. Biopsy sites with relatively good yield include the pleura, liver, bone marrow, lymph nodes, and lung via transbronchial biopsies; the yield is likely to be increased in the setting of associated clinical or laboratory abnormalities. Histopathology typically demonstrates granulomatous inflammation. Tuberculous granulomas characteristically contain epithelioid macrophages, Langhans giant cells, and lymphocytes, and the centers often have characteristic caseation ("cheese-like") necrosis. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> - In general, the approach to antimicrobial therapy for treatment of miliary TB is the same as for pulmonary TB using a traditional multidrug regimen (≥6 months); modifications may be warranted in the setting of drug-resistant TB. In addition, longer duration of therapy may be warranted for children, immunocompromised hosts, patients with a large organism burden, and patients with a slow microbiologic or clinical response. Longer duration of therapy is also warranted for patients with disease involving the central nervous system, some patients with bone or joint disease, and some cases of lymphadenitis. Surgical intervention may be needed for diagnostic and/or therapeutic management in some cases. (See <a class="local">'Treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Proudfoot AT, Akhtar AJ, Douglas AC, Horne NW. Miliary tuberculosis in adults. Br Med J 1969; 2:273.</a></li><li><a class="nounderline abstract_t">Kim JH, Langston AA, Gallis HA. Miliary tuberculosis: epidemiology, clinical manifestations, diagnosis, and outcome. Rev Infect Dis 1990; 12:583.</a></li><li><a class="nounderline abstract_t">Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002; 6:55.</a></li><li><a class="nounderline abstract_t">Asada Y, Hayashi T, Sumiyoshi A, et al. Miliary tuberculosis presenting as fever and jaundice with hepatic failure. Hum Pathol 1991; 22:92.</a></li><li><a class="nounderline abstract_t">Harvey C, Eykyn S, Davidson C. Rigors in tuberculosis. Postgrad Med J 1993; 69:724.</a></li><li><a class="nounderline abstract_t">Lowry KJ, Stephan KT, Davis CE. Miliary tuberculosis presenting with rigors and developing unusual cutaneous manifestations. Cutis 1999; 64:23.</a></li><li><a class="nounderline abstract_t">Sydow M, Schauer A, Crozier TA, Burchardi H. Multiple organ failure in generalized disseminated tuberculosis. Respir Med 1992; 86:517.</a></li><li><a class="nounderline abstract_t">Ahuja SS, Ahuja SK, Phelps KR, et al. Hemodynamic confirmation of septic shock in disseminated tuberculosis. Crit Care Med 1992; 20:901.</a></li><li><a class="nounderline abstract_t">Piqueras AR, Marruecos L, Artigas A, Rodriguez C. Miliary tuberculosis and adult respiratory distress syndrome. Intensive Care Med 1987; 13:175.</a></li><li><a class="nounderline abstract_t">Mohan A, Sharma SK, Pande JN. Acute respiratory distress syndrome (ARDS) in miliary tuberculosis: a twelve year experience. Indian J Chest Dis Allied Sci 1996; 38:157.</a></li><li><a class="nounderline abstract_t">Heap MJ, Bion JF, Hunter KR. Miliary tuberculosis and the adult respiratory distress syndrome. Respir Med 1989; 83:153.</a></li><li><a class="nounderline abstract_t">Lintin SN, Isaac PA. Miliary tuberculosis presenting as adult respiratory distress syndrome. Intensive Care Med 1988; 14:672.</a></li><li><a class="nounderline abstract_t">Murray HW, Tuazon CU, Kirmani N, Sheagren JN. The adult respiratory distress syndrome associated with miliary tuberculosis. Chest 1978; 73:37.</a></li><li><a class="nounderline abstract_t">Dyer RA, Chappell WA, Potgieter PD. Adult respiratory distress syndrome associated with miliary tuberculosis. Crit Care Med 1985; 13:12.</a></li><li><a class="nounderline abstract_t">Heffner JE, Strange C, Sahn SA. The impact of respiratory failure on the diagnosis of tuberculosis. Arch Intern Med 1988; 148:1103.</a></li><li><a class="nounderline abstract_t">Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. Am J Med 1990; 89:291.</a></li><li><a class="nounderline abstract_t">Gelb AF, Leffler C, Brewin A, et al. Miliary tuberculosis. Am Rev Respir Dis 1973; 108:1327.</a></li><li><a class="nounderline abstract_t">Munt PW. Miliary tuberculosis in the chemotherapy era: with a clinical review in 69 American adults. Medicine (Baltimore) 1972; 51:139.</a></li><li><a class="nounderline abstract_t">BIEHL JP. Miliary tuberculosis; a review of sixty-eight adult patients admitted to a municipal general hospital. Am Rev Tuberc 1958; 77:605.</a></li><li><a class="nounderline abstract_t">Slavin RE, Walsh TJ, Pollack AD. Late generalized tuberculosis: a clinical pathologic analysis and comparison of 100 cases in the preantibiotic and antibiotic eras. Medicine (Baltimore) 1980; 59:352.</a></li><li><a class="nounderline abstract_t">Rasheed S, Zinicola R, Watson D, et al. Intra-abdominal and gastrointestinal tuberculosis. Colorectal Dis 2007; 9:773.</a></li><li><a class="nounderline abstract_t">Ramesh J, Banait GS, Ormerod LP. Abdominal tuberculosis in a district general hospital: a retrospective review of 86 cases. QJM 2008; 101:189.</a></li><li><a class="nounderline abstract_t">Hussain W, Mutimer D, Harrison R, et al. Fulminant hepatic failure caused by tuberculosis. Gut 1995; 36:792.</a></li><li><a class="nounderline abstract_t">Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis 2005; 5:415.</a></li><li><a class="nounderline abstract_t">Gupta RK, Kohli A, Gaur V, et al. MRI of the brain in patients with miliary pulmonary tuberculosis without symptoms or signs of central nervous system involvement. Neuroradiology 1997; 39:699.</a></li><li><a class="nounderline abstract_t">Lam KY, Lo CY. A critical examination of adrenal tuberculosis and a 28-year autopsy experience of active tuberculosis. Clin Endocrinol (Oxf) 2001; 54:633.</a></li><li><a class="nounderline abstract_t">Barnes DJ, Naraqi S, Temu P, Turtle JR. Adrenal function in patients with active tuberculosis. Thorax 1989; 44:422.</a></li><li><a class="nounderline abstract_t">Hickey AJ, Gounder L, Moosa MY, Drain PK. A systematic review of hepatic tuberculosis with considerations in human immunodeficiency virus co-infection. BMC Infect Dis 2015; 15:209.</a></li><li><a class="nounderline abstract_t">Johnson AW, Mokuolu OA, Ogan O. Tuberculous laryngitis in a Nigerian child. Ann Trop Paediatr 1993; 13:91.</a></li><li><a class="nounderline abstract_t">Vomero E, Ratner SJ. Diagnosis of miliary tuberculosis by examination of middle ear discharge. Arch Otolaryngol Head Neck Surg 1988; 114:1029.</a></li><li class="breakAll">Basgoz N, Swartz MN. Infections of the thyroid gland. In: The Thyroid: A Fundamental and Clinical Text, Braverman LE, Utiger RD (Eds), Lippincott-Raven, 1996.</li><li><a class="nounderline abstract_t">Rieder HL, Kelly GD, Bloch AB, et al. Tuberculosis diagnosed at death in the United States. Chest 1991; 100:678.</a></li><li><a class="nounderline abstract_t">MILDER E, OXENHORN S, SCHLECKER A, et al. A case of miliary tuberculosis simulating acute blastic leukemia. JAMA 1961; 177:116.</a></li><li><a class="nounderline abstract_t">TWOMEY JJ, LEAVELL BS. LEUKEMOID REACTIONS TO TUBERCULOSIS. Arch Intern Med 1965; 116:21.</a></li><li><a class="nounderline abstract_t">Hunt BJ, Andrews V, Pettingale KW. The significance of pancytopenia in miliary tuberculosis. Postgrad Med J 1987; 63:801.</a></li><li><a class="nounderline abstract_t">Campo E, Condom E, Miro MJ, et al. Tuberculosis-associated hemophagocytic syndrome. A systemic process. Cancer 1986; 58:2640.</a></li><li><a class="nounderline abstract_t">Isaacs RD, Nicholson GI, Holdaway IM. Miliary tuberculosis with hypercalcaemia and raised vitamin D concentrations. Thorax 1987; 42:555.</a></li><li><a class="nounderline abstract_t">Felson B. A new look at pattern recognition of diffuse pulmonary disease. AJR Am J Roentgenol 1979; 133:183.</a></li><li><a class="nounderline abstract_t">Felson B. The roentgen diagnosis of disseminated pulmonary alveolar diseases. Semin Roentgenol 1967; 2:3.</a></li><li><a class="nounderline abstract_t">Kwong JS, Carignan S, Kang EY, et al. Miliary tuberculosis. Diagnostic accuracy of chest radiography. Chest 1996; 110:339.</a></li><li><a class="nounderline abstract_t">Optican RJ, Ost A, Ravin CE. High-resolution computed tomography in the diagnosis of miliary tuberculosis. Chest 1992; 102:941.</a></li><li><a class="nounderline abstract_t">Voloudaki AE, Tritou IN, Magkanas EG, et al. HRCT in miliary lung disease. Acta Radiol 1999; 40:451.</a></li><li><a class="nounderline abstract_t">Lee KS, Kim TS, Han J, et al. Diffuse micronodular lung disease: HRCT and pathologic findings. J Comput Assist Tomogr 1999; 23:99.</a></li><li><a class="nounderline abstract_t">Lee J, Lim JK, Seo H, et al. Clinical relevance of ground glass opacity in 105 patients with miliary tuberculosis. Respir Med 2014; 108:924.</a></li><li><a class="nounderline abstract_t">Malik K, Dedhia HV, Bishop H. Clinical utility of PET-FDG imaging in detecting malignancy in pulmonary lesions. Chest 1996; 110:95S.</a></li><li><a class="nounderline abstract_t">Hara T, Kosaka N, Suzuki T, et al. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 2003; 124:893.</a></li><li><a class="nounderline abstract_t">Heysell SK, Thomas TA, Sifri CD, et al. 18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series. BMC Pulm Med 2013; 13:14.</a></li><li><a class="nounderline abstract_t">Kao CH, Wang SJ, Liao SQ, et al. Usefulness of gallium-67-citrate scans in patients with acute disseminated tuberculosis and comparison with chest x-rays. J Nucl Med 1993; 34:1918.</a></li><li><a class="nounderline abstract_t">Shinnick TM, Good RC. Diagnostic mycobacteriology laboratory practices. Clin Infect Dis 1995; 21:291.</a></li><li><a class="nounderline abstract_t">Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017; 64:e1.</a></li><li><a class="nounderline abstract_t">Hanna BA, Walters SB, Bonk SJ, Tick LJ. Recovery of mycobacteria from blood in mycobacteria growth indicator tube and Lowenstein-Jensen slant after lysis-centrifugation. J Clin Microbiol 1995; 33:3315.</a></li><li><a class="nounderline abstract_t">Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376.</a></li><li><a class="nounderline abstract_t">Munseri PJ, Talbot EA, Bakari M, et al. The bacteraemia of disseminated tuberculosis among HIV-infected patients with prolonged fever in Tanzania. Scand J Infect Dis 2011; 43:696.</a></li><li><a class="nounderline abstract_t">Mert A, Bilir M, Tabak F, et al. Miliary tuberculosis: clinical manifestations, diagnosis and outcome in 38 adults. Respirology 2001; 6:217.</a></li><li><a class="nounderline abstract_t">Kim CH, Lim JK, Yoo SS, et al. Diagnostic performance of the QuantiFERON-TB Gold In-Tube assay and factors associated with nonpositive results in patients with miliary tuberculosis. Clin Infect Dis 2014; 58:986.</a></li><li><a class="nounderline abstract_t">Lee YM, Park KH, Kim SM, et al. Diagnostic usefulness of a T-cell-based assay in patients with miliary tuberculosis compared with those with lymph node tuberculosis. Clin Infect Dis 2013; 56:e26.</a></li><li><a class="nounderline abstract_t">Steingart KR, Henry M, Laal S, et al. A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. Thorax 2007; 62:911.</a></li><li><a class="nounderline abstract_t">Dowdy DW, Steingart KR, Pai M. Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis. PLoS Med 2011; 8:e1001074.</a></li><li><a class="nounderline abstract_t">Steingart KR, Flores LL, Dendukuri N, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med 2011; 8:e1001062.</a></li><li class="breakAll">World Health Organization. Commercial Serodiagnostic Tests for Diagnosis of Tuberculosis: Policy Statement, 2011. http://whqlibdoc.who.int/publications/2011/9789241502054_eng.pdf (Accessed on October 11, 2011).</li><li><a class="nounderline abstract_t">Willcox PA, Potgieter PD, Bateman ED, Benatar SR. Rapid diagnosis of sputum negative miliary tuberculosis using the flexible fibreoptic bronchoscope. Thorax 1986; 41:681.</a></li><li><a class="nounderline abstract_t">Pant K, Chawla R, Mann PS, Jaggi OP. Fiberbronchoscopy in smear-negative miliary tuberculosis. Chest 1989; 95:1151.</a></li><li><a class="nounderline abstract_t">Strumpf IJ, Tsang AY, Sayre JW. Re-evaluation of sputum staining for the diagnosis of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119:599.</a></li><li><a class="nounderline abstract_t">Stender H, Mollerup TA, Lund K, et al. Direct detection and identification of Mycobacterium tuberculosis in smear-positive sputum samples by fluorescence in situ hybridization (FISH) using peptide nucleic acid (PNA) probes. Int J Tuberc Lung Dis 1999; 3:830.</a></li><li><a class="nounderline abstract_t">Tortoli E, Cichero P, Piersimoni C, et al. Use of BACTEC MGIT 960 for recovery of mycobacteria from clinical specimens: multicenter study. J Clin Microbiol 1999; 37:3578.</a></li><li><a class="nounderline abstract_t">Balada-Llasat JM, Kamboj K, Pancholi P. Identification of mycobacteria from solid and liquid media by matrix-assisted laser desorption ionization-time of flight mass spectrometry in the clinical laboratory. J Clin Microbiol 2013; 51:2875.</a></li><li><a class="nounderline abstract_t">Crump JA, Ramadhani HO, Morrissey AB, et al. Bacteremic disseminated tuberculosis in sub-saharan Africa: a prospective cohort study. Clin Infect Dis 2012; 55:242.</a></li><li class="breakAll">Shinnick TM, Jonas V. Molecular approaches to the diagnosis of tuberculosis. In: Tuberculosis: pathogenesis, protection and control, Bloom BR (Ed), American Society of Microbiology Press, Washington DC 1994. p.517.</li><li><a class="nounderline abstract_t">Clarridge JE 3rd, Shawar RM, Shinnick TM, Plikaytis BB. Large-scale use of polymerase chain reaction for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory. J Clin Microbiol 1993; 31:2049.</a></li><li><a class="nounderline abstract_t">Kaneko K, Onodera O, Miyatake T, Tsuji S. Rapid diagnosis of tuberculous meningitis by polymerase chain reaction (PCR). Neurology 1990; 40:1617.</a></li><li><a class="nounderline abstract_t">Akcan Y, Tuncer S, Hayran M, et al. PCR on disseminated tuberculosis in bone marrow and liver biopsy specimens: correlation to histopathological and clinical diagnosis. Scand J Infect Dis 1997; 29:271.</a></li><li><a class="nounderline abstract_t">Folgueira L, Delgado R, Palenque E, et al. Rapid diagnosis of Mycobacterium tuberculosis bacteremia by PCR. J Clin Microbiol 1996; 34:512.</a></li><li><a class="nounderline abstract_t">Schluger NW, Rom WN. The polymerase chain reaction in the diagnosis and evaluation of pulmonary infections. Am J Respir Crit Care Med 1995; 152:11.</a></li><li><a class="nounderline abstract_t">Aceti A, Zanetti S, Mura MS, et al. Identification of HIV patients with active pulmonary tuberculosis using urine based polymerase chain reaction assay. Thorax 1999; 54:145.</a></li><li class="breakAll">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340:367.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009; 58:7.</a></li><li><a class="nounderline abstract_t">Kohli M, Schiller I, Dendukuri N, et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database Syst Rev 2018; 8:CD012768.</a></li><li><a class="nounderline abstract_t">Shah M, Martinson NA, Chaisson RE, et al. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. J Clin Microbiol 2010; 48:2972.</a></li><li><a class="nounderline abstract_t">Talbot E, Munseri P, Teixeira P, et al. Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One 2012; 7:e32876.</a></li><li><a class="nounderline abstract_t">Nakiyingi L, Moodley VM, Manabe YC, et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr 2014; 66:270.</a></li><li><a class="nounderline abstract_t">Peter JG, Theron G, van Zyl-Smit R, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J 2012; 40:1211.</a></li><li><a class="nounderline abstract_t">Peter JG, Zijenah LS, Chanda D, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet 2016; 387:1187.</a></li><li><a class="nounderline abstract_t">Lawn SD, Gupta-Wright A. Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated TB with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications. Trans R Soc Trop Med Hyg 2016; 110:180.</a></li><li><a class="nounderline abstract_t">Bjerrum S, Broger T, Székely R, et al. Diagnostic Accuracy of a Novel and Rapid Lipoarabinomannan Test for Diagnosing Tuberculosis Among People With Human Immunodeficiency Virus. Open Forum Infect Dis 2020; 7:ofz530.</a></li><li><a class="nounderline abstract_t">Sossen B, Broger T, Kerkhoff AD, et al. "SILVAMP TB LAM" Rapid Urine Tuberculosis Test Predicts Mortality in Patients Hospitalized With Human Immunodeficiency Virus in South Africa. Clin Infect Dis 2020; 71:1973.</a></li><li><a class="nounderline abstract_t">Dalpiaz G, Piolanti M, Cancellieri A, Barozzi L. Diffuse granulomatous lung disease: combined pathological-HRCT approach. Radiol Med 2014; 119:54.</a></li><li><a class="nounderline abstract_t">American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986; 134:355.</a></li><li><a class="nounderline abstract_t">Carr W, Kurbatova E, Starks A, et al. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:285.</a></li><li><a class="nounderline abstract_t">Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021; 384:1705.</a></li><li><a class="nounderline abstract_t">Oktay MF, Topcu I, Senyigit A, et al. Follow-up results in tuberculous cervical lymphadenitis. J Laryngol Otol 2006; 120:129.</a></li><li><a class="nounderline abstract_t">Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis 1997; 25:872.</a></li><li><a class="nounderline abstract_t">Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 2014; 371:1121.</a></li><li><a class="nounderline abstract_t">FALK A. U. S. VETERANS ADMINISTRATION-ARMED FORCES COOPERATIVE STUDY ON THE CHEMOTHERAPY OF TUBERCULOSIS.13. TUBERCULOUS MENINGITIS IN ADULTS, WITH SPECIAL REFERENCE TO SURVIVAL, NEUROLOGIC RESIDUALS, AND WORK STATUS. Am Rev Respir Dis 1965; 91:823.</a></li><li><a class="nounderline abstract_t">von Reyn CF, Kimambo S, Mtei L, et al. Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. Int J Tuberc Lung Dis 2011; 15:1087.</a></li><li><a class="nounderline abstract_t">Sahn SA, Neff TA. Miliary tuberculosis. Am J Med 1974; 56:494.</a></li><li><a class="nounderline abstract_t">Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698.</a></li></ol></div><div id="topicVersionRevision">Topic 8024 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5780453" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Miliary tuberculosis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2385765" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Miliary tuberculosis: epidemiology, clinical manifestations, diagnosis, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11931402" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985084" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Miliary tuberculosis presenting as fever and jaundice with hepatic failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8255841" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Rigors in tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10431668" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Miliary tuberculosis presenting with rigors and developing unusual cutaneous manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1470711" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Multiple organ failure in generalized disseminated tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1597048" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hemodynamic confirmation of septic shock in disseminated tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3584648" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Miliary tuberculosis and adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8987289" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acute respiratory distress syndrome (ARDS) in miliary tuberculosis: a twelve year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2602600" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Miliary tuberculosis and the adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3183196" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Miliary tuberculosis presenting as adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/620556" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The adult respiratory distress syndrome associated with miliary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3965242" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Adult respiratory distress syndrome associated with miliary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3130000" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The impact of respiratory failure on the diagnosis of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2393033" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4201630" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Miliary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5013636" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Miliary tuberculosis in the chemotherapy era: with a clinical review in 69 American adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13521258" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Miliary tuberculosis; a review of sixty-eight adult patients admitted to a municipal general hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7432152" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Late generalized tuberculosis: a clinical pathologic analysis and comparison of 100 cases in the preantibiotic and antibiotic eras.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868413" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Intra-abdominal and gastrointestinal tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18234735" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Abdominal tuberculosis in a district general hospital: a retrospective review of 86 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797133" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fulminant hepatic failure caused by tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15978528" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Miliary tuberculosis: new insights into an old disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9351104" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : MRI of the brain in patients with miliary pulmonary tuberculosis without symptoms or signs of central nervous system involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380494" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A critical examination of adrenal tuberculosis and a 28-year autopsy experience of active tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2763243" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adrenal function in patients with active tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25943103" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A systematic review of hepatic tuberculosis with considerations in human immunodeficiency virus co-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7681653" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tuberculous laryngitis in a Nigerian child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3408570" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnosis of miliary tuberculosis by examination of middle ear discharge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3408570" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Diagnosis of miliary tuberculosis by examination of middle ear discharge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1889256" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Tuberculosis diagnosed at death in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13770623" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A case of miliary tuberculosis simulating acute blastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14338950" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : LEUKEMOID REACTIONS TO TUBERCULOSIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3444806" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The significance of pancytopenia in miliary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3779613" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Tuberculosis-associated hemophagocytic syndrome. A systemic process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3438901" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Miliary tuberculosis with hypercalcaemia and raised vitamin D concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/110078" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A new look at pattern recognition of diffuse pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The roentgen diagnosis of disseminated pulmonary alveolar diseases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8697830" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Miliary tuberculosis. Diagnostic accuracy of chest radiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516427" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : High-resolution computed tomography in the diagnosis of miliary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10394878" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : HRCT in miliary lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10050818" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Diffuse micronodular lung disease: HRCT and pathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24787005" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical relevance of ground glass opacity in 105 patients with miliary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical utility of PET-FDG imaging in detecting malignancy in pulmonary lesions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970014" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23514625" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : 18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8229234" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Usefulness of gallium-67-citrate scans in patients with acute disseminated tuberculosis and comparison with chest x-rays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8562734" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Diagnostic mycobacteriology laboratory practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27932390" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8586725" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Recovery of mycobacteria from blood in mycobacteria growth indicator tube and Lowenstein-Jensen slant after lysis-centrifugation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764337" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21563879" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The bacteraemia of disseminated tuberculosis among HIV-infected patients with prolonged fever in Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555380" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Miliary tuberculosis: clinical manifestations, diagnosis and outcome in 38 adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24457341" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diagnostic performance of the QuantiFERON-TB Gold In-Tube assay and factors associated with nonpositive results in patients with miliary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23051762" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Diagnostic usefulness of a T-cell-based assay in patients with miliary tuberculosis compared with those with lymph node tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17675320" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21857810" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21857806" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21857806" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3097866" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Rapid diagnosis of sputum negative miliary tuberculosis using the flexible fibreoptic bronchoscope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2707073" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Fiberbronchoscopy in smear-negative miliary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/87141" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Re-evaluation of sputum staining for the diagnosis of pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10488893" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Direct detection and identification of Mycobacterium tuberculosis in smear-positive sputum samples by fluorescence in situ hybridization (FISH) using peptide nucleic acid (PNA) probes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10523555" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Use of BACTEC MGIT 960 for recovery of mycobacteria from clinical specimens: multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23804379" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Identification of mycobacteria from solid and liquid media by matrix-assisted laser desorption ionization-time of flight mass spectrometry in the clinical laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22511551" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bacteremic disseminated tuberculosis in sub-saharan Africa: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22511551" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Bacteremic disseminated tuberculosis in sub-saharan Africa: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8370729" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Large-scale use of polymerase chain reaction for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2120615" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Rapid diagnosis of tuberculous meningitis by polymerase chain reaction (PCR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9255888" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : PCR on disseminated tuberculosis in bone marrow and liver biopsy specimens: correlation to histopathological and clinical diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8904404" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Rapid diagnosis of Mycobacterium tuberculosis bacteremia by PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599808" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The polymerase chain reaction in the diagnosis and evaluation of pulmonary infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325920" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Identification of HIV patients with active pulmonary tuberculosis using urine based polymerase chain reaction assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325920" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Identification of HIV patients with active pulmonary tuberculosis using urine based polymerase chain reaction assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9929528" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Tuberculosis in patients with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19145221" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30148542" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Xpert®MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20534796" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412939" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24675585" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22362849" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26970721" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26884498" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated TB with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31976353" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Diagnostic Accuracy of a Novel and Rapid Lipoarabinomannan Test for Diagnosing Tuberculosis Among People With Human Immunodeficiency Virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31917832" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : "SILVAMP TB LAM" Rapid Urine Tuberculosis Test Predicts Mortality in Patients Hospitalized With Human Immunodeficiency Virus in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24488691" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Diffuse granulomatous lung disease: combined pathological-HRCT approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3527010" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33951360" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16359138" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Follow-up results in tuberculous cervical lymphadenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9356803" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25178809" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14294703" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : U. S. VETERANS ADMINISTRATION-ARMED FORCES COOPERATIVE STUDY ON THE CHEMOTHERAPY OF TUBERCULOSIS.13. TUBERCULOUS MENINGITIS IN ADULTS, WITH SPECIAL REFERENCE TO SURVIVAL, NEUROLOGIC RESIDUALS, AND WORK STATUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21740673" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4206484" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Miliary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8309034" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
